When oral morphine fails in cancer pain: The role of the alternative routes

Abstract

References

Hanks GW , De Conno F , Ripamonti C , et al : Morphine in cancer pain: modes of administration. BMJ. 1996;312:823-826.

Coyle N , Adelhardt J , Foley KM , et al : Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage. 1990;5:83-93.

Cherny NJ , Chang V , Frager G , et al : Opioid pharmacotherapy in the management of cancer pain. Cancer. 1995;76:1288-1293.

Mercadante S , Genovese G , Kargar JA , et al : Home palliative care: results in 1991 versus 1988. J Pain Symptom Manage. 1992;7:414-418.

Bruera E : Alternate routes for home opioid therapy. Pain Clinical Updates. 1993;1:1-4.

McDonald P , Graham P , Clayton M , et al : Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliat Med. 1991;5:323-329.

Drexel H , Dzien A , Spiegel RW , et al : Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain. 1989;36:169-176.

Bruera E , Ripamonti C : Alternate routes of administration of opioids. In Patt RB (ed.): Cancer pain. Philadelphia, JB Lippincott Co., 1993; 161-184.

Coyle N , Cherny NI , Portenoy RK : Subcutaneous opioid infusions at home. Oncology. 1994;8:31-32.

10.

Moulin DE , Kreeft JH , Murray-Parsons N , et al : Comparison of continuous subcutaneous hydromorphone infusions for management of cancer pain. Lancet. 1991;337:465-468.

11.

Waldman CS , Eason JR , Rambohul E , et al : Serum morphine levels: a comparison between continuous subcutaneous infusion and continuous intravenous infusion in postoperative patients. Anesthesia. 1984;39:768-771.

12.

Nelson KA , Glare PA , Walsh D , et al : A prospective, within-patient, cross-over study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage. 1997;13:262-267.

13.

Mercadante S : Pain treatment and outcome in advanced cancer patients followed at home. Cancer. In press.

14.

Grond S , Zech D , Schug SA , et al : Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage. 1991;6:411-422.

15.

Schug SA , Zech D , Grond S , et al : A long term survey of morphine in cancer pain patients. J Pain Symptom Manage. 1992;7:259-266.

16.

Zech DFJ , Grond S , Lynch J , et al : Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63:65-76.

17.

Tiseo PJ , Thaler HT , Iapin J , et al : Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain. 1995;61:47-54.

18.

Mercadante S : The role of morphine metabolites in cancer pain. Palliat Med. In press.

19.

Kalso E , Heiskanen T , Rantio M , et al : Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain. 1996;67:443-449.

20.

Glare P : Problems with opiates in cancer pain: parenteral opioids. Support Care Cancer. 1997;5:445-450.

21.

Singer M , Noonan KR : Continuous intravenous infusion of fentanyl: case reports of use in patients with advanced cancer and intractable pain. J Pain Symptom Manage. 1993;8:215-220.

22.

Paix A , Coleman A , Lees J , et al : Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain. 1995;63:263-269.

23.

Mercadante S , Caligara M , Sapio M , et al : Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. J Pain Symptom Manage. 1997;13:241-244.

24.

Bruera E , Fainsinger RL , Moore M , et al : Local toxicity with subcutaneous methadone. Experience of two centers. Pain. 1991;45:141-143.

25.

De Conno F , Ripamonti C , Saita L , et al : Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol. 1995;13:1004-1008.

26.

Gorman DJ : Opioid analgesics in the management of pain in patients with cancer: an update. Palliat Med. 1991;5:277-294.

27.

Warren D : Practical use of rectal medications in palliative care. J Pain Symptom Manage. 1996;11:378-387.

28.

Campbell WI : Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST continuous 100 mg. J Clin Pharm Ther. 1996;21:65-71.

29.

Maloney CM , Kesner RK , Klein G , et al : The rectal administration of MS Contin: clinical implications of use in end stage cancer. Am J Hosp Care. 1989;6:34-35.

30.

Babul N , Darke AC , Anslow JA , et al : Pharmacokinetics of two novel rectal controlled-release morphine formulations. J Pain Symptom Manage. 1992;7:400-405.

31.

Kaiko RF , Fitsmartin RD , Thomas GB , et al : The bioavailability of morphine in controlled-release 30 mg tables per rectum compared with immediate-release 30 mg rectal suppositories and controlled-release 30 mg oral tablets. Pharmacotherapy. 1992;12:107-113.

32.

Babul N , Darke AC : Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. Clin Pharmacol Ther. 1993;54:286-292.

33.

Leow KP , Smith MT , Eatt JA , et al : Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit. 1991;14:479-484.

34.

Ripamonti C , Zecca E , Brunelli C , et al : Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol. 1995;6:841-843.

35.

Bruera E , Watanabe S , Fainsinger RL , et al : Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain. 1995;62:141-146.

36.

Portenoy RK , Southam M , Gupta SK , et al : Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology. 1993;78:36-43.

37.

Lehmann KA , Zech D : Transdermal fentanyl. J Pain Symptom Manage. 1992;7:8-16.

38.

MacDonald N : Commentary. J Pain Symptom Manage. 1993;8:320-321.

39.

Bruera E , Pereira J , Watanabe S , et al : Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;78:852-857.

40.

Zech D , Grond S , Lynch J , et al : Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain. 1992;50:293-301.

41.

Donner B , Zenz M , Tryba M , et al : Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64:527-534.

42.

Korte W , de Stoutz N , Morant R : Day-today titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage. 1996;11:139-146.

43.

Patt B : Commentary. J Pain Symptom Manage. 1993;8:322-323.

44.

Hanks GW , Fallon MT : Transdermal fentanyl in cancer pain: conversion from oral morphine. J Pain Symptom Manage. 1995;10:87.

45.

Ahmedzai S , Brooks D : TTS-Fentanyl Comparative Trial Group. Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage. 1997;13:254-261.

46.

The TTS-Fentanyl Multicentre Study Group . Transdermal fentanyl in cancer pain. J Drug Dev. 1994;6:93-97.

47.

Hunt R : Transdermal fentanyl and the opioid withdrawal syndrome. Palliat Med. 1994;4:347-348.

48.

Davies AN , Bond C : Transdermal fentanyl and the opioid withdrawal syndrome. Palliat Med. 1994;4:348.

49.

Grond S , Zech D , Lehmann KA , et al : Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain. 1997;69:191-198.

50.

Zenz M , Donner B , Strumpf M : Withdrawal symptoms during therapy with transdermal fentanyl? J Pain Symptom Manage. 1994;9:54-55.

51.

Jeal W , Benfield P : Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997;53:109-138.

52.

Stanley TH , Ashburn MA : Novel delivery systems: oral transmucosal and intranasal transmucosal. J Pain Symptom Manage. 1992;7:163-171.

53.

Weinberg DS , Inturrisi CE , Redenberg B , et al : Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther. 1988;44:335-342.

54.

Osborne R , Joel S , Trew D , et al : Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-metabolite. Clin Pharmacol Ther. 1990;47:12-19.

55.

Robinson JM , Wilkie DJ , Campbell B : Sublingual and oral morphine administration. Nurs Clin North Am. 1995;30:725-743.

56.

Mercadante S : Letter. J Palliat Care. 1992;8:51-52.

57.

Manara AR , Shelly MP , Quinn KG , et al : Pharmacokinetics of morphine following administration by the buccal route. Br J Anaesth. 1989;62:498-502.

58.

Cleary JF : Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin Oncol. 1997;24 (suppl. 16): 13-16.

59.

Kunz KM , Theisen JA , Schoeder ME : Severe episodic pain: management with sublingual sufentanil. J Pain Symptom Manage. 1993;8:189.

60.

Striebel HW , Oelmann T , Spies C , et al : Patient-controlled intranasal analgesia: a method for noninvasive postoperative pain management. Anesth Analg. 1996;83:548-551.

61.

Fine PG , Marcus M , De Boer AJ , et al : An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain. 1991;45:149-153.

62.

Fine PG : Fentanyl in the treatment of cancer pain. Semin Oncol. 1997;24(suppl. 16): 20-27.

63.

Maasod AR , Thomas SH : Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. Br J Clin Pharmacol. 1996: 41:250-252.

64.

Zeppetella G : Nebulized morphine in the palliation of dyspnea. Palliat Med. 1997;11:267-275.

65.

Davis CL , Penn K , A’Hern R , et al : Single-dose randomized controlled trial of nebulized morphine in patients with cancer-related breathlessness. Palliat Med. 1996;10:64-65.

66.

Quelch PC , Faulkner DE , Yun JWS : Nebulized opioids in the management of dyspnea. J Palliat Care. 1997;13:48-52.

67.

Farncombe M , Chatter S , Gillin A : The use of nebulized opioids for breathlessness: a chart review. Palliat Med. 1994;8:306-312.

68.

Lang E , Jedeikin R : Acute respiratory depression as a complication of nebulised morphine. Can J Anaesth. 1998;45:60-62.

69.

Mercadante S , Agnello A , Armata MG , et al : The inappropriate use of the epidural route in cancer pain. J Pain Symptom Manage. 1997;13:352-355.

70.

Hogan Q , Haddox JD , Abram S , et al : Epidural opiates and local anesthetics for the management of cancer pain. Pain. 1991: 46:271-279.

71.

Zech DFJ , Grond S , Lynch J , et al : Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63:65-76.

72.

Samuelsson H , Malberg F , Eriksson M , et al : Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage. 1995;10:105-112.

73.

van Dongen RTM , Crul BJP , De Bock M : Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain. 1993;55:119-123.

74.

Krames ES : Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Symptom Manage. 1993;8:36-46.

75.

Du Pen SL , Williams AR : The dilemma of conversion from systemic to epidural morphine: a proposed conversion tool for treatment of cancer pain. Pain. 1994;56:113-118.

76.

Gourlay GK , Plummer JL , Cherry DA , et al : Comparison or intermittent bolus with continuous infusion of epidural morphine in the treatment of severe cancer pain. Pain. 1991;47:135-140.

77.

Nitescu P , Sjoberg M , Appelgren L , et al : Complications of intrathecal opioids and bupivacaine in the treatment of “refractory” cancer pain. Clin J Pain. 1995;11:45-62.

78.

Gesten Y , Vainio A , Pégurier AM : Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer. Acta Anaesthesiol Scand. 1997;47:12-17.

79.

Crul BJ , Delhaas EM : Technical complications during long-term subarachnoid or epidural administration of morphine in terminally ill cancer patients: a review of 140 cases. Reg Anesth. 1991;16:209-213.

80.

Nitescu P , Appelgren L , Linder LE , et al : Epidural versus intrathecal morphine-bupivacaine: assessment of consecutive treatments in advanced cancer pain. J Pain Symptom Manage. 1990;5:18-26.

81.

Sjoberg H , Karlsson P , Nordborg C , et al : Neuropathologic findings after long-term intrathecal infusions of morphine and bupivacaine for pain treatment in cancer patients. Anesthesiology. 1992;76:173-186.

82.

Appelgren L , Nordborg C , Sjoberg M , et al : Spinal epidural metastasis: implications for spinal analgesia to treat “refractory” cancer pain. J Pain Symptom Manage. 1997;13:25-42.

83.

Chrubasik J , Chrubasik S , Martin E : The ideal epidural opioid: fact or fantasy. Eur J Anaesth. 1993;10:79-100.

84.

Amer S , Amer B : Differential effects of epidural morphine in the treatment of cancer related pain. Acta Anesthesiol Scand. 1985;29:32-36.

85.

Samuelsson H , Hedner T : Pain characterization in cancer patients and the analgesic response to epidural morphine. Pain. 1991;46:3-8.

86.

Erdine S , Aldemir T : Long-term results of peridural morphine in 225 patients. Pain. 1991;45:155-159.

87.

Mercadante S : Controversies in the spinal treatment in advanced cancer patients. Support Care Cancer. In press.

88.

Karavelis A , Forogiou G , Selviaridis P , et al : Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. Neurosurgery. 1996;39:57-62.